{
    "clinical_study": {
        "@rank": "94042", 
        "arm_group": [
            {
                "arm_group_label": "Hepatic Impairment: Child-Pugh A", 
                "arm_group_type": "Experimental", 
                "description": "Participants with chronic liver disease and classified as Child-Pugh Grade A had a score of 5-6 (out of 15) which correlates with a good prognosis.  Each participant received one sublingual tablet of Suboxone\u00ae (2mg buprenorphine with 0.5 mg naloxone) on Day 1."
            }, 
            {
                "arm_group_label": "Hepatic Impairment: Child-Pugh B", 
                "arm_group_type": "Experimental", 
                "description": "Participants with chronic liver disease and classified as Child-Pugh Grade B had a score of 7-9 (out of 15) which correlates with significant functional liver compromise.  Each participant received one sublingual tablet of Suboxone\u00ae (2mg buprenorphine with 0.5 mg naloxone) on Day 1."
            }, 
            {
                "arm_group_label": "Hepatic Impairment: Child-Pugh C", 
                "arm_group_type": "Experimental", 
                "description": "Participants with chronic liver disease and classified as Child-Pugh Grade C had a score of 10-15 (out of 15) which correlates with decompensated liver disease.  Each participant received one sublingual tablet of Suboxone\u00ae (2mg buprenorphine with 0.5 mg naloxone) on Day 1."
            }, 
            {
                "arm_group_label": "HCV Without Hepatic Impairment", 
                "arm_group_type": "Experimental", 
                "description": "Participants with hepatitis C virus (HCV) without hepatic impairment received one sublingual tablet of Suboxone\u00ae (2mg buprenorphine with 0.5 mg naloxone) on Day 1."
            }, 
            {
                "arm_group_label": "No Hepatic Disease or Impairment", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants with no hepatic disease or impairment received one sublingual tablet of Suboxone\u00ae (2mg buprenorphine with 0.5 mg naloxone) on Day 1."
            }
        ], 
        "brief_summary": {
            "textblock": "Pharmacokinetics of Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic\n      Impairment and in HCV-Seropositive Subjects, and in Healthy Volunteers."
        }, 
        "brief_title": "Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hepatic Failure", 
            "Hepatic Impairment", 
            "Chronic Hepatitis C Infection With Hepatic Coma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatic Encephalopathy", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Liver Failure", 
                "Hepatitis C, Chronic", 
                "Liver Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "This will be a multi-center, open-label study.  After providing informed consent, subjects\n      will undergo an outpatient screening period of up to 21 days.  Screening procedures will\n      include an assessment of mental status which will be repeated before dosing.  Eligible\n      subjects will then undergo hospital intake procedures and reside at the investigational site\n      until Day 5.  Subjects will be enrolled in 5-treatment groups as follows: (1) Group 1:\n      Subjects with hepatic impairment classified as Child-Pugh A; (2) Group 2: Subjects with\n      hepatic impairment classified as Child-Pugh B; (3) Group 3:  Subjects with hepatic\n      impairment classified as Child-Pugh C; (4) Group 4:  Subjects with Hepatitis C Virus (HCV)\n      infection but without hepatic impairment; and (5) Group 5:  Subjects without hepatic disease\n      or impairment. Group 5 is used as a control group"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females between the ages of 18 and 65 years, inclusive\n\n          -  Females should be surgically sterile, 2 years post-menopausal or have a negative\n             plasma \u03b2-human chorionic gonadotropin (\u03b2-hCG) pregnancy test.  Subjects of\n             child-bearing potential must take reasonable precautions during the study to avoid\n             pregnancy by agreeing to remain abstinent or to practice double-barrier forms of\n             birth control from the time of informed consent through the last study visit.  A\n             negative plasma pregnancy (\u03b2-hCG) test at Screening and upon admission to the\n             investigational site.  Testing for \u03b2-hCG will need to be timed to ensure a negative\n             pregnancy result at Day 1.\n\n          -  Male subject agrees to use barrier contraception and spermicide when engaging in\n             sexual activity with a female of child-bearing potential for at least 28 days after\n             the study medication dose.\n\n          -  Male subject agrees to refrain from sperm donations for the entire duration of the\n             study and for at least 90 days after the study drug dose.\n\n          -  Body mass index (BMI) of \u2265 18 to \u2264 33 kg^m2.\n\n          -  Subject agrees to the conditions of the study and signs the informed consent form\n\n        Exclusion Criteria:\n\n          -  Medical conditions:  (a) pregnancy; and (b) breastfeeding\n\n          -  Psychiatric conditions:  (a) current treatment for opioid addiction with substitution\n             therapies; (b) active history of bipolar I, bipolar II, schizophrenia,\n             schizophreniform; schizoaffective; mania, hypomania, or severe post-traumatic stress\n             disorder; and (c) presence of suicidal behavior within the year before informed\n             consent or suicidal intent within the 30 days before informed consent as documented\n             by the Columbia Suicide Severity Rating Scale\n\n          -  Hypersensitivity to opioids, defined as intractable vomiting, severe constipation, or\n             severe pruritus after opioid treatment\n\n          -  Subject has a known intolerance or hypersensitivity to buprenorphine or naloxone or\n             any excipients in the Suboxone tablet formulation\n\n          -  In the judgment of the investigator, any other condition that would preclude safe,\n             useful, or consistent participation in the study\n\n          -  Use of any investigational medication or investigational medical device in the 30\n             days before informed consent\n\n          -  Hepatic encephalopathy greater than West Haven Grade 2\n\n          -  Donation of > 250 ml of blood within previous 30 days\n\n          -  Systolic BP \u2264 90 or \u2265 160 mmHg and/or Diastolic BP < 60 mmHg or > 100 mmHg\n\n          -  History of cholecystectomy\n\n          -  History or current acquired immunodeficiency syndrome (AIDS) or human\n             immunodeficiency virus (HIV) antibodies\n\n          -  Estimated creatinine clearance rate (eC Cr) using Cockcroft-Gault formula < 60 mL/min\n\n          -  More than 1 missed appointment during Screening\n\n          -  Currently under mandate by the criminal justice system or Child and Family Services\n             to participate in drug abuse treatment\n\n          -  Participation in drug or alcohol dependence treatment in the 30 days before informed\n             consent\n\n          -  Positive urine drug screen result for amphetamines, methamphetamine, barbiturates,\n             benzodiazepines, buprenorphine, cannabinoids, cocaine, methadone, opioids, oxycodone,\n             or phencyclidine which, in the judgment of the investigator, is indicative of\n             non-prescribed drug use; and/or positive urine alcohol screen result in which, in the\n             judgment of the investigator, is indicative of alcohol abuse or alcoholism\n\n          -  Consumption of prohibited medications within 1 week of informed consent, including\n             buprenorphine\n\n          -  Consumption of grapefruit and grapefruit juice for at least one week before the study\n             dose and until the end of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01846455", 
            "org_study_id": "RB-US-08-0003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Hepatic Impairment: Child-Pugh A", 
                    "Hepatic Impairment: Child-Pugh B", 
                    "Hepatic Impairment: Child-Pugh C", 
                    "HCV Without Hepatic Impairment", 
                    "No Hepatic Disease or Impairment"
                ], 
                "description": "Each participant will receive a single sublingual dose of Suboxone\u00ae on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.", 
                "intervention_name": "2.0mg Buprenorphine/0.5mg Naloxone", 
                "intervention_type": "Drug", 
                "other_name": "Suboxone\u00ae"
            }, 
            {
                "arm_group_label": [
                    "Hepatic Impairment: Child-Pugh A", 
                    "Hepatic Impairment: Child-Pugh B", 
                    "Hepatic Impairment: Child-Pugh C", 
                    "HCV Without Hepatic Impairment", 
                    "No Hepatic Disease or Impairment"
                ], 
                "description": "Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone\u00ae administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone\u00ae administration.", 
                "intervention_name": "Promethazine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Promethazine", 
                "Diphenhydramine", 
                "Buprenorphine", 
                "Naloxone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hepatic", 
            "Hepatitis C Virus", 
            "Suboxone", 
            "Buprenorphine", 
            "Naloxone"
        ], 
        "lastchanged_date": "August 20, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hialeah", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33014-3616"
                    }, 
                    "name": "Clinical Pharmacology of Miami, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Orlando Clinical Research Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }, 
                    "name": "American Research Corporation (ARC)"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers", 
        "overall_official": [
            {
                "affiliation": "Clinical Pharmacology of Miami, Inc.", 
                "last_name": "Thomas Lasseter, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Orlando Clinical Research Center", 
                "last_name": "Thomas Marabury, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "American Research Corporation (ARC)", 
                "last_name": "Eric J. Lawitz, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC0-last) of buprenorphine, norbuprenorphine and naloxone", 
                "safety_issue": "No", 
                "time_frame": "before dosing (time 0; Baseline) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours after dosing"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (CMAX) of buprenorphine, norbuprenorphine and naloxone", 
                "safety_issue": "No", 
                "time_frame": "before dosing (time 0; Baseline) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours after dosing"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) of buprenorphine, norbuprenorphine and naloxone", 
                "safety_issue": "No", 
                "time_frame": "before dosing (time 0; Baseline) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours after dosing"
            }, 
            {
                "measure": "Time to reach the maximum plasma concentration (tmax) of buprenorphine, norbuprenorphine and naloxone", 
                "safety_issue": "No", 
                "time_frame": "before dosing (time 0; Baseline) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours after dosing"
            }, 
            {
                "measure": "Terminal elimination rate-constant (\u03bbz) of buprenorphine, norbuprenorphine and naloxone", 
                "safety_issue": "No", 
                "time_frame": "before dosing (time 0; Baseline) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours after dosing"
            }, 
            {
                "measure": "Terminal elimination half-life (t1/2) of buprenorphine, norbuprenorphine and naloxone", 
                "safety_issue": "No", 
                "time_frame": "before dosing (time 0; Baseline) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours after dosing"
            }, 
            {
                "measure": "Apparent body clearance (CL/F) of buprenorphine", 
                "safety_issue": "No", 
                "time_frame": "before dosing (time 0; Baseline) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours after dosing"
            }, 
            {
                "measure": "Apparent volume of distribution (Vdz/F) of buprenorphine", 
                "safety_issue": "No", 
                "time_frame": "before dosing (time 0; Baseline) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours after dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01846455"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Reckitt Benckiser Pharmaceuticals Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Reckitt Benckiser Pharmaceuticals Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}